On May 22, 2026 Oxford Vacmedix (OVM), the UK biotech company developing novel immunotherapies to treat cancer reported that the Phase 1b dose expansion part of the Phase 1 trial of OVM-200 will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago at the end of May. The poster presentation will be part of the session on Developmental Therapeutics – Immunotherapy. This follows the publication of Phase 1a, which established dosing, in a Lancet group journal earlier this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Phase 1 clinical trial of OVM-200 is a multicentre, open-label, first-in-human evaluation of OVM-200, an immunotherapy developed using Oxford Vacmedix’s Recombinant Overlapping Peptide (ROP) therapeutic platform. 36 patients with advanced NSCLC (non-small cell lung cancer) ovarian cancer, or prostate cancer and with no HLA restrictions, were treated in the trial. The results show:

Excellent Safety Profile (primary endpoint): OVM-200 is very well tolerated with no serious adverse drug reactions or no dose-limiting toxicities. The only adverse effects were Grade 1 injection-site reactions.
Very strong Immunogenicity (secondary endpoint): the immune responses for both antibodies and for T cells were very strong even in an advanced Stage IV patient population.
Therapeutic Dose established (secondary endpoint) based on the immune response, the 2mg dose selected in Phase 1a was chosen for expanded immunisations of up to 11 doses of 2mg in Phase 1b.
Early observations of clinical efficacy with stable disease in NSCLC and PSA responses in prostate cancer following progression to other therapies.
Professor Martin Forster, Chief Investigator at University College Hospital, London, said:

We are very impressed with the results of this Phase 1 trial for OVM-200. In particular, seeing six months stable disease in a Stage IV lung cancer patient is a very promising result, for follow up. We look forward to further development with Phase 2 trials of OVM-200.

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

The completion of this clinical trial of OVM-200 marks an important milestone for the company. We are of course very grateful for the participation of the patients and the dedication of the staff in the clinics in this first trial of OVM-200. We are already in discussions about investment to fund Phase 2 development.

(Press release, Oxford Vacmedix, MAY 22, 2026, View Source;utm_medium=rss&utm_campaign=ovm-200-phase-1-clinical-trial-accepted-for-presentation-at-asco [SID1234666014])